Retransplantation after post-transplant lymphoproliferative disorders: An OPTN/UNOS database analysis

American Journal of Transplantation

Volumn 6, Issue 11, 2006, Pages 2743-2749

  Johnson, S R ^a   Cherikh, W S ^b   Kauffman, H M ^b   Pavlakis, M ^a   Hanto, D W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNITED NETWORK FOR ORGAN SHARING   (United States)

Author keywords

Epstein Barr virus; Lymphoproliferative disease; Malignancy; Post transplant lymphoproliferative disorder; Retransplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; DATA BASE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETRANSPLANTATION;

DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; REOPERATION; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION IMMUNOLOGY; WAITING LISTS;

EID: 33750005062     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01543.x     Document Type: Article

References (26)

1. Howard RJ, Patton PR, Reed AI et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 1923-1928.
2. Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70: 1335-1342.
3. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913.
4. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
5. Green M. Management of Epstein-Barr virus-induced posttransplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001; 1: 103-108.
6. Schaar CG, van der Pijl JW, van Hoek B et al. Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. Transplantation 2001; 71: 47-52.
7. Trofe J, Buell JF, Beebe TM et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5(4 Pt 1): 775-780.
8. Demircin G, Rees L. Retransplantation after post-transplant lymphoproliferative disease. Pediatr Nephrol 1997; 11: 358-360.
9. Karras A, Thervet E, Le Meur Y, Baudet-Bonneville V, Kessler M, Legendre C. Successful renal retransplantation after posttransplant lymphoproliferative disease. Am J Transplant 2004; 4: 1904-1909.
10. Birkeland SA, Hamilton-Dutoit S, Bendtzen K. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: Duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation. Transplantation 2003; 76: 153-158.
11. Hickey DP, Nalesnik MA, Vivas CA et al. Renal retransplantation in patients who lost their allografts during management of previous post-transplant lymphoproliferative disease. Clin Transplantation 1990; 4: 187-190.
12. Raj R, Frost AE. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): A single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant 2005; 24: 671-679.
13. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
14. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993-998.
15. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293.
16. Jain A, Nalesnik M, Reyes J et al. Posttransplant lymphoproliferative disorders in liver transplantation: A 20-year experience. Ann Surg 2002; 236: 429-436.
17. Duvoux C, Pageaux GP, Vanlemmens C et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: An analysis of 480 patients. Transplantation 2002; 74: 1103-1109.
18. Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: A new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000; 69: 430-432.
19. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
20. Akcali Z, Ozyilkan O, Moray G, Emiroglu R, Haberal M. Treatment results in renal transplant recipients with non-Hodgkin's lymphoma. Transplant Proc 2003; 35: 1404-1407.
21. Shapiro R, Nalesnik M, McCauley J et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 1999; 68: 1851-1854.
22. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001; 33 (Suppl 1): S38-S46.
23. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: Incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242-1249.
24. Aull MJ, Buell JF, Trofe J et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004; 78: 1676-1682.
25. Hanto DW. Retransplantation after post-transplant lymphoproliferative diseases (PTLD): When is it safe? Am J Transplant 2004; 4: 1733-1734.
26. Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: Evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5(4 Pt 2): 874-886.